Education
About Us
Working with TipRanks
Follow Us
IGC Pharma (IGC)
:IGC
IGC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.25 - $0.50
Previous CloseN/A
Volume646.33K
Average Volume (3M)1.11M
Market Cap
$39.38M
Enterprise Value$22.89M
Total Cash (Recent Filing)$454.00K
Total Debt (Recent Filing)$202.00K
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Nov 12, 2025EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding90,809,110
10 Day Avg. Volume2,111,580
30 Day Avg. Volume1,113,223
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue17.25
Enterprise Value/Gross Profit37.52
Enterprise Value/Ebitda-3.60
Forecast
1Y Price Target
$0.50Price Target Upside16.28% Upside
Rating ConsensusHold
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Clinical TrialsIGC reported positive interim results from its Phase 2 trial for IGC-AD1, showing a significant reduction in agitation compared to placebo in patients with Alzheimer's disease.
Growth OpportunitiesThe company's strategic expansion into the $75 billion wellness industry with the launch of the Holiby brand offers new growth opportunities.
Market PotentialThe large market potential for Alzheimer's treatments presents high rewards despite the risks, given the growing number of Americans affected by the disease.
Bears Say
Market RisksThe large market potential for Alzheimer's disease treatment, due to the absence of a known cure and a growing number of patients, presents high rewards for the risks involved.
IGC Pharma News
IGC FAQ
What was IGC Pharma’s price range in the past 12 months?
IGC Pharma lowest stock price was $0.25 and its highest was $0.50 in the past 12 months.
What is IGC Pharma’s market cap?
IGC Pharma’s market cap is $39.38M.
When is IGC Pharma’s upcoming earnings report date?
IGC Pharma’s upcoming earnings report date is Nov 12, 2025 which is in 65 days.
How were IGC Pharma’s earnings last quarter?
Currently, no data Available
Is IGC Pharma overvalued?
According to Wall Street analysts IGC Pharma’s price is currently Undervalued.
Does IGC Pharma pay dividends?
IGC Pharma does not currently pay dividends.
What is IGC Pharma’s EPS estimate?
IGC Pharma’s EPS estimate is -0.02.
How many shares outstanding does IGC Pharma have?
IGC Pharma has 90,809,110 shares outstanding.
What happened to IGC Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of IGC Pharma?
Currently, no hedge funds are holding shares in IGC
IGC Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$0.50 (16.28% Upside)
$0.50 (16.28% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.50%
12-Months-Change
Fundamentals
Return on Equity
-90.87%
Trailing 12-Months
Asset Growth
-25.02%
Trailing 12-Months
Company Description
IGC Pharma
IGC Pharma (IGC) is a biopharmaceutical company focused on developing innovative therapies for the treatment of chronic pain and neurological disorders. The company operates primarily in the pharmaceutical and biotechnology sectors, leveraging its proprietary formulations and technologies to create novel medicinal products. IGC’s core offerings include cannabinoid-based therapeutics that aim to address unmet medical needs, particularly in areas such as pain management and behavioral health.
IGC Earnings Call
Q4 2025
0:00 / 0:00
Technical Analysis
NN
―
Rcm Technologies
―
Steel Partners Holdings
―
Mammoth Energy Services
―
FTAI Infrastructure Incorporation
―
Ownership Overview
1.04% Insiders
1.34% Mutual Funds
0.16% Other Institutional Investors
96.94% Public Companies and
Individual Investors